A Phase 3 interventional study of Lansoprazole 15 mg and Tegoprazan 25 mg in Preventive Peptic Ulcer, sponsored by HK inno.N Corporation. Completed at 2 sites in South Korea. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by HK inno.N Corporation · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Peptic Ulcer with a site in Korea, Republic of — 4 open to participants now, 5 under way, 3 of them phase 3. Peptic Ulcer · Korea, Republic of.
Among the 19 studies in Peptic Ulcer with a site in Korea, Republic of, this one is the 6th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2021, is one of 7 in phase 3, and was the 15th registered.
146 studies on the registry are indexed under Peptic Ulcer; 25 are open to participants now.
Browse Peptic Ulcer studies →4 of the 19 studies in Peptic Ulcer with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Onconic Therapeutics Inc. · Sites in Korea, Republic of
Ages 19+
Duk-Woo Park, MD · Sites in Korea, Republic of
Ages 19+
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of, Indonesia
Ages 19+
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 18 Peptic Ulcer studies recruiting now, 11 (61%) set no upper age limit and 7 (39%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 392 is above the median of 165 across 105 interventional studies indexed under Peptic Ulcer.
Median enrollment 344 across the 16 interventional studies, 455 across the 3 observational. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 19 have an industry lead sponsor. The 10 most frequent:
HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.
HK inno.N Corporation has 1 study filed under Peptic Ulcer — fewer than ten, so there is no comparison to draw.
3 of the studies in Peptic Ulcer with a site in Korea, Republic of that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06439563Phase 3Onconic Therapeutics Inc.Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers | 2027-08 |
| NCT06284876Phase 3Il-Yang Pharm. Co., Ltd.Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer | 2027-08-30 |
| NCT07558707Daewoong Pharmaceutical Co. LTD.Fexuclue for Prevention of NSAIDs-Induced Peptic Ulcer in Real-World Practice | 2027-04-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 19 studies in Peptic Ulcer with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to confirm the non-inferiority of Tegoprazan 25 mg, compared to Lansoprazole 15 mg, to prevent gastroduodenal ulcers and verify the safety of tegoprazan following oral administration of tegoprazan 25 mg QD or lansoprazole 15 mg QD in patients on long-term treatment with NSAIDs.
This is a double-blind, randomized, active-controlled, phase 3 study. Subjects will be randomly assigned to one of the two treatment groups (tegoprazan 25 mg, lansoprazole 15 mg).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tegoprazan 25mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.
Drug: Tegoprazan 25 mg
Lansoprazole 15mg capsules will be orally administered, once a day, with NSAIDs, for up to 6 months.
Drug: Lansoprazole 15 mg
Lansoprazole 15 mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.
Tegoprazan 25 mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.
Proportion of subjects with gastric and/or duodenal ulcers at Week 24
The proportion of subjects with gastric and/or duodenal ulcers on upper GI endoscopy at Week 24
Time frame: week 24
Proportion of subjects without NSAID-related GI symptoms at Weeks 4, 12, and 24
GI symptoms are as follows; Heartburn, Regurgitation, Upper abdominal pain or discomfort
Time frame: week 4, 12, 24
Plan to share: No
Ran from May 2021 to primary completion in Jul 2025, 49 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tegoprazan